Please login to the form below

Not currently logged in
Email:
Password:

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

Halozyme to resume pancreatic cancer study

There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to recruit another 100 patients to add

Latest news

  • Halozyme halts pancreatic cancer trial Halozyme halts pancreatic cancer trial

    Halozyme halts pancreatic cancer trial. The biopharma company is investigating PEGPH20’ s links to blood clot. ... Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the candidate's safety.

  • Baxter re-files HyQvia for immunodeficiency in US Baxter re-files HyQvia for immunodeficiency in US

    HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for

  • Roche wins EU approval for injectable Herceptin Roche wins EU approval for injectable Herceptin

    Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.

  • Roche's Perjeta backed in EU for breast cancer Roche's Perjeta backed in EU for breast cancer

    Roche is also developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of trastuzumab - partnered with Halozyme Therapeutics - that is also in the latter stages of development.

  • Roche's T-DM1 activity in breast cancer Roche's T-DM1 activity in breast cancer "outstanding"

    Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products

  • Pharma deals during December 2014 Pharma deals during December 2014

    Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics